Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin’s lymphoma

Rituximab is an anti-CD20 humanized monoclonal antibody widely used in the treatment of B-cell non-Hodgkin’s lymphomas (NHLs). Its mechanism of action is related with complement function—complement mediated cytotoxicity. CD46, CD55, and CD59 are complement regulatory proteins. The aim of this study...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medical oncology (Northwood, London, England) London, England), 2010-09, Vol.27 (3), p.743-746
Hauptverfasser:	Dzietczenia, Justyna, Wróbel, Tomasz, Mazur, Grzegorz, Poręba, Rafał, Jaźwiec, Bożena, Kuliczkowski, Kazimierz
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Murine-Derived - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use CD55 Antigens - blood CD55 Antigens - immunology CD59 Antigens - blood CD59 Antigens - immunology Complement Activation Cyclophosphamide - administration & dosage Doxorubicin - administration & dosage Drug Monitoring Drug Resistance, Neoplasm - genetics Female Hematology Humans Internal Medicine Lymphoma, Follicular - drug therapy Lymphoma, Follicular - immunology Lymphoma, Follicular - metabolism Lymphoma, Follicular - pathology Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - immunology Lymphoma, Large B-Cell, Diffuse - metabolism Lymphoma, Large B-Cell, Diffuse - pathology Male Medicine Medicine & Public Health Membrane Cofactor Protein - blood Membrane Cofactor Protein - immunology Middle Aged Oncology Original Paper Pathology Prednisone - administration & dosage Rituximab Tumor Burden Vincristine - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!